Skip to main content

Table 3 List of clinical trials included for PFS analysis

From: Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Study No. patients Median PFS (months) HR
CA209-067 n + i = 314
n = 316
n + i = 11.5
n = 6.93
HR 0.79
CA209-227 (PFS TMB High) n + i = 101
n = 102
1 yr
n + i = 42%
n = 29%
HR 0.75
CA209-227 (PFS PD-L1 > 1%) n + i = 396
n = 396
n + i = 5.1
n = 4.2
HR 0.83